Phase I Study of Cell Therapies for the Treatment of Patients With Relapsed or Refractory AML or High-risk MDS
Phase 1 Unknown
24 enrolled
RVU120 in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome
Phase 1 Unknown
112 enrolled
A Study to Assess Safety and Preliminary Efficacy of LP-108 Combined With Azacitidine In Subjects With AML, MDS, CMML
Phase 1 Unknown
198 enrolled
A Study of APG-115 Alone or Combined With Azacitidine in Patients With AML, CMML, or MDS
Phase 1/2 Unknown
69 enrolled
Antigen-specific T Cell Therapy for AML or MDS Patients With Relapsed Disease After Allo-HCT
Phase 1/2 Unknown
22 enrolled
Oral Adherence in Hematological Oncology Agents and Impact on Comorbid Therapy Adherence
Phase NA Unknown
30 enrolled
MoTD
Phase 2 Unknown
400 enrolled
Clinical Trial Evaluating the Safety of the TQB2928 Injection Combination Therapy
Phase 1 Unknown
48 enrolled
Study of BC3402 in Combination With Azacitidine in Patients With MDS and CMML
Phase 1 Unknown
32 enrolled
Safety Evaluation Study for Patients With Polycythemia Vera
Phase 1 Unknown
6 enrolled
A Study of IMM01 Combined With Azacitidine in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome
Phase 1/2 Unknown
126 enrolled
Avapritinib in CBF-AML With KIT Mutations
Phase 2 Unknown
50 enrolled
Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis Unresponsive to Optimal Symptomatic Treatment
Phase 3 Unknown
140 enrolled
Venetoclax+Azacytidine+Modified BUCY Conditioning Regimen for Acute Myeloid Leukemia and Myelodysplastic Syndromes Undergoing Allo-HSCT
Phase 2 Unknown
70 enrolled
A Clinical Study of 6MW3211 Monotherapy or Combination Therapy for AML or MDS
Phase 1/2 Unknown
120 enrolled
MYELOCARTOCH
Phase NA Unknown
300 enrolled
Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide
Phase 1 Unknown
38 enrolled
Enhanced Palliative Care in MDS and AML
Phase NA Unknown
90 enrolled
Dose Reduced Dasatinib (70 mg Daily) as First-line Treatment for Newly Diagnosed CML-CP
Phase 4 Unknown
65 enrolled
Clinical Study of TQB2618 Injection in Combination With Demethylation Drugs in Patients With Recurrent/Refractory Acute Myeloid Leukemia, Myelodysplastic Syndromes
Phase 1 Unknown
73 enrolled
Safety and Early Efficacy Study of TBX-2400 in Patients With AML or Myelofibrosis
Phase 1 Unknown
10 enrolled
Safety and Efficiency of γδ T Cell Against Hematological Malignancies After Allo-HSCT
Phase 1/2 Unknown
20 enrolled
ESAAC
Phase NA Unknown
800 enrolled
Gentulizumab in Relapsed/Refractory Acute Myelogenous Leukemia or Myelodysplastic Syndrome
Phase 1 Unknown
58 enrolled
SUSTRENIM
Phase 4 Unknown
450 enrolled
Aza With or Without ATRA in Newly Diagnosed Unfit AML or Intermediate,High or Very High Risk MDS
Phase 2/3 Unknown
180 enrolled
Study of Flonoltinib Maleate Tablets in the Treatment of Proliferative Bone Marrow Tumors
Phase 1 Unknown
31 enrolled
Myeloid Mutations Register in R/R CML
Phase NA Unknown
29 enrolled
Ex-vivo Primed Memory Donor Lymphocyte Infusion to Boost Anti-viral Immunity After T-cell Depleted HSCT
Phase 1/2 Unknown
20 enrolled
A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Max-40279-01 in Combination With Azacitidine (AZA) in Patients With Myelodysplastic Syndrome (MDS) or Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
Phase 1/2 Unknown
100 enrolled
Induction Chemotherapy Sequential Sintilimab Combined With Dual Epigenetic Drugs for ENKTL-HLH
Phase 2 Unknown
37 enrolled
MyPal ePRO-based Early Palliative Care System in Adult Patients With Hematologic Malignancies
Phase NA Unknown
300 enrolled
JSP191 Antibody Conditioning Regimen in MDS/AML Subjects Undergoing Allogenic Hematopoietic Stem Cell Transplantation
Phase 1 Unknown
40 enrolled
Sodium Stibogluconate in the MDS/AML With One of the 65 Defined p53 Mutations
Phase 2 Unknown
5 enrolled
Treo/Flu/TBI With Donor Stem Cell Transplant for Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
Phase 2 Unknown
102 enrolled 12 charts
Alisertib in Treating Patients With Myelofibrosis or Relapsed or Refractory Acute Megakaryoblastic Leukemia
Phase NA Unknown
26 enrolled 10 charts
Vidaza and Valproic Acid Post Allogeneic Transplant for High Risk AML and MDS
Phase 2 Unknown
50 enrolled
CALVI
Phase 3 Unknown
140 enrolled
Investigator-initiated Clinical Trial (Phase II) of Cancer Vaccine "Dainippon Sumitomo Phama(DSP)-7888" for Acute Myeloid Leukemia Patients.
Phase 2 Unknown
100 enrolled
CarPAs
Phase 2 Unknown
50 enrolled
Cellular Immunotherapy for Patients With High Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia
Phase 1/2 Unknown
5 enrolled
READIT
Phase 2 Unknown
100 enrolled
LaserMasto
Phase NA Unknown
34 enrolled
MSIT
Phase 3 Unknown
118 enrolled
KRT-232 Compared to Ruxolitinib in Patients With Phlebotomy-Dependent Polycythemia Vera
Phase 2 Unknown
20 enrolled
GPED Regimen for Relapsed/Refractory or Advanced ENKTCL
Phase 2 Unknown
29 enrolled
A Study of TQ05105 Tablets in Subjects With Myeloproliferative Neoplasms
Phase 1 Unknown
50 enrolled
PRO-DLI
Phase 2 Unknown
124 enrolled
The Role of Ruxolitinib in Secondary Acute Myelogenous Leukemia Evolving From Myeloproliferative Neoplasm
Phase 1/2 Unknown
17 enrolled
Study to Evaluate Tolerability, Safety, Pharmacokinetics and Preliminary Efficacy of PF-114 for Oral Administration in Adults With Ph+ Chronic Myeloid Leukemia, Which is Resistant to the 2-nd Generation Bcr-Abl Inhibitors or Has T315I Mutation in the BCR-ABL Gene
Phase 1/2 Unknown
65 enrolled